Genetron Holdings (Genetron Holdings) EBIT : $-97.92 Mil (TTM As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings EBIT?

Genetron Holdings's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2022 was $-25.33 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2022 was $-97.92 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Genetron Holdings's annualized ROC % for the quarter that ended in Jun. 2022 was -104.75%. Genetron Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -187.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Genetron Holdings EBIT Historical Data

The historical data trend for Genetron Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetron Holdings EBIT Chart

Genetron Holdings Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-34.79

-95.62

-468.50

-78.09

-100.28

Genetron Holdings Quarterly Data
	Dec17	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22
EBIT	Get a 7-Day Free Trial													-19.26	-25.91	-27.42	-25.33	-

Competitive Comparison of Genetron Holdings's EBIT

For the Diagnostics & Research subindustry, Genetron Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genetron Holdings's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetron Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Genetron Holdings's EV-to-EBIT falls into.

Genetron Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-97.92 Mil.

Genetron Holdings (NAS:GTH) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Genetron Holdings's annualized ROC % for the quarter that ended in Jun. 2022 is calculated as:

	ROC % (Q: Jun. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2022 )	+	Invested Capital (Q: Jun. 2022 ))	/ count )
=	-96.408 * ( 1 - 0% )	/	( (91.694	+	92.383)	/ 2 )
=	-96.408	/	92.0385
=	-104.75 %

where

	Invested Capital		(Q: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	209.412	-	29.595	-	( 88.123	-	max(0, 39.327	-	164.615	+	88.123	))
=	91.694

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	194.672	-	31.689	-	( 70.6	-	max(0, 52.291	-	147.832	+	70.6	))
=	92.383

Note: The Operating Income data used here is four times the quarterly (Jun. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Genetron Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2022		Q: Jun. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-101.312	/	( ( (28.31 + max(25.805, 0))	+	(30.626 + max(23.271, 0)) )	/	2 )
=	-101.312	/	( ( 54.115	+	53.897 )	/	2 )
=	-101.312	/	54.006
=	-187.59 %

where Working Capital is:

	Working Capital		(Q: Mar. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(44.358	+	6.776	+	5.636)	-	(29.595	+	1.37	+	0)
=	25.805

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(46.161	+	8.218	+	4.464)	-	(31.689	+	3.883	+	-7.105427357601E-15)
=	23.271

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Genetron Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2022 )
	=	-97.923	/	0.000
	=	%

Genetron Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Genetron Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetron Holdings (Genetron Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206

Website

https://www.genetronhealth.com

Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.